SWOG clinical trial number
SWOG-9457

Paclitaxel (Taxol®) and Carboplatin for Advanced Transitional Cell Carcinoma of the Urothelium, Phase II

Closed
Phase
Accrual
86%
Published
Abbreviated Title
Advanced Bladder
Activated
07/15/1996
Closed
04/15/2000

Research committees

Genitourinary Cancer

Publication Information Expand/Collapse

2005

Phase II trial of carboplatin and paclitaxel in cisplatin-pretreated advanced transitional cell carcinoma: a Southwest Oncology Group study

UN Vaishampayan;JR Faulkner;EJ Small;BG Redman;WL Keiser;DP Petrylak;ED Crawford Cancer 104(8):1627-1632

2003

Southwest Oncology Group studies in bladder cancer

ED Crawford;DP Wood;DP Petrylak;J Scott;CA Coltman, Jr;D Raghavan Cancer Supplement 97(8):2099-2108

2000

A Southwest Oncology Group study of paclitaxel and carboplatin for advanced transitional cell carcinoma: The importance of survival as a clinical trial endpoint

EJ Small;D Lew;BG Redman;DP Petrylak;N Hammond;HM Gross;JA Eastham;ED Crawford Journal of Clinical Oncology 18(13):2537-2544

1999

Carboplatin and paclitaxel (CARBO/TAX) for advanced transitional cell carcinoma (TCC) of the urothelium.

EJ Small;D Lew;DP Petrylak;ED Crawford Proc of the American Society of Clinical Oncology 18:333a(#1280)

Other Clinical Trials

SWOG Clinical Trial Number
S2312

A Phase III Study of Cabazitaxel with or without Carboplatin in Patients with metastatic castrate-resistant prostate cancer (mCRPC), Stratified by Aggressive Variant Signature
Research Committee(s)
Genitourinary Cancer
Activated
09/03/2024
Accrual
0%
Open
Phase
SWOG Clinical Trial Number
S2210

S2210, "Targeted Neoadjuvant Treatment for Patients with Localized Prostate Cancer and Germline DNA Repair Deficiency"
Research Committee(s)
Genitourinary Cancer
Activated
08/14/2023
Accrual
7%
Open
Phase
SWOG Clinical Trial Number
S2200

S2200, A Phase II Randomized Trial of Cabozantinib with or Without Atezolizumab in Patients with Advanced Papillary Renal Cell Carcinoma: PAPMET2
Research Committee(s)
Genitourinary Cancer
Activated
09/19/2022
Accrual
14%
Open
Phase